These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In search of the ideal antiemetic. Seegenschmiedt MH Acta Oncol; 2004 Sep; 43 Suppl 15():13-8. PubMed ID: 15370625 [No Abstract] [Full Text] [Related]
4. [Treatment of nausea nad vomiting in palliative medicine]. Bausewein C Z Arztl Fortbild Qualitatssich; 2000 Sep; 94(7):569-73. PubMed ID: 11048341 [TBL] [Abstract][Full Text] [Related]
6. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens. Trigg ME; Inverso DM Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391 [TBL] [Abstract][Full Text] [Related]
7. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients? de Wit R; Aapro M; Blower PR Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653 [TBL] [Abstract][Full Text] [Related]
8. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866 [TBL] [Abstract][Full Text] [Related]
9. Antiemetic strategies for high-dose chemoradiotherapy-induced nausea and vomiting. Spitzer TR; Grunberg SM; Dicato MA Support Care Cancer; 1998 May; 6(3):233-6. PubMed ID: 9629875 [TBL] [Abstract][Full Text] [Related]
10. New perspectives in antiemetic treatment. Herrstedt J Support Care Cancer; 1996 Nov; 4(6):416-9. PubMed ID: 8961471 [TBL] [Abstract][Full Text] [Related]
11. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist. Egan AP; Taggart JR; Bender CM Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124 [TBL] [Abstract][Full Text] [Related]
13. 5HT3-receptor antagonists as antiemetics in cancer. Drug Ther Bull; 2005 Aug; 43(8):57-62. PubMed ID: 16111085 [TBL] [Abstract][Full Text] [Related]
14. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron. Kidgell AE; Butcher ME; Brown GW Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933 [No Abstract] [Full Text] [Related]
15. Oral 5-HT3-receptor antagonists: expanding the options for Medicare outpatients. Dempsey CL; Shillington AC; Goliak M J Am Pharm Assoc (Wash); 1998; 38(5):515-6. PubMed ID: 9782682 [No Abstract] [Full Text] [Related]
16. Blueprint for the control of radiation-induced nausea and vomiting. Discussion. Horiot JC Acta Oncol; 2004 Sep; 43 Suppl 15():23-4. PubMed ID: 15370627 [No Abstract] [Full Text] [Related]
17. [Prevention and treatment of postoperative nausea and postoperative vomiting with tropisetron]. Hennes HJ Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):628-31. PubMed ID: 9445562 [No Abstract] [Full Text] [Related]
18. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877 [TBL] [Abstract][Full Text] [Related]
19. Antiemetic action of 5-HT3 receptor antagonists: review of preclinical and clinical results with ICS 205-930. Gamse R Cancer Treat Rev; 1990 Sep; 17(2-3):301-5. PubMed ID: 2272046 [TBL] [Abstract][Full Text] [Related]